


Consolidated Financial Results Presentation Materials for the Fiscal Year Ended March 2026

May 12, 2026

DAICEL CORPORATION



Results of FY2026/3 Financial Results (YoY)

<u>Net Sales</u>	<u>579.6 bn yen</u>	<u>(-1.2%)</u>
<u>Operating Income</u>	<u>42.1 bn yen</u>	<u>(-31.0%)</u>
<u>EBITDA</u>	<u>85.4 bn yen</u>	<u>(-16.6%)</u>
<u>Profit Attributable to Owners of Parent</u>	<u>10.2 bn yen</u>	<u>(-79.4%)</u>

Exchange Rate USD/JPY : 151 yen
(FY2025/3 USD/JPY : 153 yen)

【Net Sales】 Down

- (+) In the Safety business, sales volume of airbag inflator increased mainly in China and India.
- (-) Sales volume of acetate tow in the Materials business decreased due to inventory adjustments mainly in local manufacturers, despite steady demand from major customers.

【Operating Income】 Down

- (+) In the Safety Business, productivity improvement at a production site in the U.S, and cost reduction effects in China contributed to operating income.
- (-) Impact of carried over inventory from the previous fiscal year and a decline in sales of acetate tow in the Materials Business, and increased depreciation expenses due to the operation of the new plant of Engineering Plastics business.

【Profit Attributable to Owners of Parent】 Down

- (-) Recorded an impairment loss related to the new (second) plant currently under construction.

Revised Forecasts of FY2027/3 (YoY)

<u>Net Sales</u>	<u>595.0 bn yen</u>	<u>(+2.7 %)</u>
<u>Operating Income</u>	<u>42.5 bn yen</u>	<u>(+1.0 %)</u>
<u>EBITDA</u>	<u>87.0 bn yen</u>	<u>(+1.9 %)</u>
<u>Profit Attributable to Owners of Parent</u>	<u>32.0 bn yen</u>	<u>(+214.3 %)</u>

Exchange Rate (Forecast) USD/JPY : 150 yen
(Previous Forecast USD/JPY : 151 yen)

*These data do not reflect the impact of deterioration of Middle East.

【Net Sales】 Up

(+) Increase in sales volume of Engineering Plastics and airbag inflator for automobile

(+) In the Materials business, net sales are expected to increase due to the completion of inventory adjustments at local manufacturers until 2nd half of the FY2027/3.

【Operating Income】 Up

(+) In the High-Performance Polymers business, operating income for FY2027/3 is expected to increase, reflecting factors such reduction in the scale of scheduled maintenance.

(-) Operating income is expected to decrease due to factors such as falling sales prices resulting from intensifying competition in the local acetate tow market and rising prices for pulp, a key raw material.

FY2026/3: Annual dividends 60 yen per share (Unchanged from the previous forecast)

FY2027/3: Decided on the cancellation of treasury stock of 10.8 million shares. Dividend policy will be announced in conjunction with the Mid-term Management Strategy.

Shareholders Return

Impairment Loss on the Second Plant of Cyclic Olefin Copolymer (COC)

■ Outline

As disclosed in our timely disclosure on March 26, 2026, regarding COC resin (cyclic olefin copolymer), which is manufactured and sold by our consolidated subsidiary TOPAS Advanced Polymers GmbH in Germany, we have determined that profitability has declined due to factors such as delayed growth in demand and increased investment in the second plant resulting from soaring construction costs. Consequently, we have conservatively reassessed the asset value and decided to record an impairment loss on the second plant currently under construction.

- Construction is ongoing, with the aim of commencing operations during fiscal year 2027.
- Impairment Loss: 32.4 billion yen (EUR/JPY 175)
- Production Capacity: 20,000 tons (ref. existing plant: 15,000 tons)

【The Background of Decision for Second Plant Construction】

The existing plant produces products for multiple applications, including eco-friendly packaging and medical uses. (At the time the decision was made to construct in the second plant, the existing plant had an operating rate of 97% with a production capacity of 10,000 tons.) Although demand growth had initially been anticipated around 2025, it became clear in 2022 that only an existing plant would not be able to meet the strong demand, therefore we had been constructing a new (second) COC resin production plant with the aim of launching it in 2023 (as originally planned). Following the enforcement of the EU Packaging and Packaging Waste Regulation (PPWR) in February 2025, the market's shift toward environmentally friendly packaging is now progressing with a target of 2030. As a result, the anticipated increase in demand has been slower than originally expected.

Cyclic Olefin Copolymer (COC)

【Features and Main Applications】

- COC is a glass-clear and extremely pure amorphous plastics. It has features of excellent moisture barrier, low dissolution and low adsorption, widely used for packaging and medical application.
- COC is used for medical and pharmaceutical packaging, drug delivery, medical equipment, health monitoring device, sustainable packaging (polyolefin (PO) shrink films for PET bottles, PO monomaterial packaging films).

Revision of Business Plan for Cyclic Olefin Copolymer (COC)

■ Ongoing Status

- Construction Progress: Based on the revised construction schedule, we are constructing a second plant with efforts to minimize initial troubles and ensuring long-term stable operation.
- Market Condition : As the demand for eco-friendly packaging and medical uses remains on a recovery trend, the operating rate of the existing plant is maintained at around 80%. Sales volume of COC for eco-friendly packaging have been on an upward trend since 4Q of FY2026/3, and we also expect a steady demand expansion for medical applications.

■ Strategy for Future Growth

We aim to start operation of second plant with a safe and reliable to strengthen the foundation for stable supply. In addition, we are restructuring the production and supply framework, including the existing plant, and improving profitability to transform the business into one that can generate stable profits.

Furthermore, supported by the background of structural demand growth, such as progress in aging society and rising demand for self-management medication, introduction of EU PPWR, and rising environmental awareness, we promote to expand sales for medical and eco-friendly packaging applications to achieve mid-and long term sales growth and strengthen profitability.


Initiative: Optimization of the Production Mix

Currently, the existing plant manufactures products for multiple applications, resulting in time losses associated with frequent changeovers. Following the start of operation of the second plant, **the existing plant will focus on high-value-added applications, while the second plant will concentrate on production for eco-friendly packaging applications.** Through this optimization, we aim to respond to growing demand for COC toward 2030, improve production efficiency, and strengthen profitability.

【Investment Payback】


- The payback period for second plant is **projected to be completed in fiscal year 2033** (calculated based on incremental EBITDA from the construction of second plant)
- From 2026 through the early 2030s, growing demand for eco-friendly packaging and medical devices is expected to drive market expansion, with the COC market size projected to grow at a CAGR of over 5%.

Sales and EBITDA Plan for COC Plants
(existing and second plants)



Initiatives to Achieve Stable Operation at Carbon Monoxide (CO) Plant

In FY2026/3, we completed countermeasures for the coal pre-crushing process, including reinforcement of hammer materials. Additional stabilization measures around the coal mill, after pre-crushing process, are scheduled for the planned shutdown maintenance in May 2026, then stabilization of coal material handling is expected to be completed as planned. We will also improve the reliability by enhancement of backup systems of slurry charge pump auxiliary equipment in the gasification facilities, establishing a solid foundation for stable operations.



* These countermeasures are planned to be implemented in May 2026.

【Impact of CO plant trouble occurred in FY2026/3】

Unit: Billion Yen

	FY2026/3	FY2027/3 Forecasts	Change
Impact of CO plant trouble	-5.4	-	+5.4
Acetic acid price mix impact	0.7	-	-0.7
Inventory carryover impact	-1.0	-1.0	-
Total	-5.8	-1.0	+4.7

■ Strategic Focus and Structural Reform

We classify our businesses into “Next-Generation,” “Growth,” “Foundation,” and “Reform” through portfolio management to ensure strategic focus. We had completed approximately 70% of our structural reform initiatives by the end of FY2026/3. By implementing the remaining structural reforms, we establish a solid foundation for growth and aim to achieve both sales growth and improved profitability of “Growth” businesses.

Initiatives

FY2026/3

- **Production optimization of acetate tow among three production sites (Aboshi, Ohtake and Toyama Filter Tow)**
 - Wholly owned subsidiary of Toyama Filter Tow Ltd. (April 2025)
- **Expansion of the product portfolio in the Engineering Plastics business**
 - Partnership with Mitsui Chemicals Inc. for marketing operations for Engineering Plastic business (January 2026)
- **Maximization of business value by optimizing business portfolio and business transfer**
 - Withdrawal from polystyrene business (transfer of Daicel Corporation’s Equity Interest in Toyo Styrene Co., Ltd.) (March 2026)
 - Share Transfer of Daicel Pack Systems Ltd. (withdrawal from food containers, industrial containers, and cushioning materials) (March 2026)
 - Withdrawal from optical lenses (transfer to a best owner) (March 2026)

FY2027/3

- **Accelerate growth initiatives and fully leverage the company’s resources**
 - Business integration of Polyplastics Co., Ltd. into Daicel Corporation (April 2026)
- Regarding growth investment, we steadily promote initiatives aimed at delivering tangible results in our Growth and Next-Generation businesses.
- Regarding partnership with other companies, we shift from considering stage to action phase to realize projects.

Financial Results



Unit: Billion Yen

	25/3 Results	26/3 Results	Y on Y		26/3 Forecasts*
			Change	%	
Net Sales	586.5	579.6	-6.9	-1.2%	576.0
Operating Income	61.0	42.1	-18.9	-31.0%	41.0
Ordinary Income	62.3	45.1	-17.2	-27.6%	43.0
Profit Attributable to Owners of Parent	49.5	10.2	-39.3	-79.4%	10.0
Exchange Rate USD/JPY	153	151	*These forecasts were announced on March 26, 2026. (Exchange Rate USD/JPY ¥150)		


	2025/3 Results	2026/3 Results
EBITDA	102.4	85.4
ROE	13.8%	2.8%
ROIC	6.1%	4.2%
ROA	6.0%	1.2%
EPS (Yen)	181.44	38.75

Result / Analysis of EBITDA

Result (Y on Y)

- Quantity impact was negative (-2.1 billion yen) due to a decrease in sales volume of acetate tow.
- Price impact (except for exchange rate impact) was negative (-5.2 billion yen) due to lower selling prices driven by decreased sales volumes of acetate tow to local manufacturers and weaker acetic acid market conditions.
- CO plant impact was positive (6.5 billion yen) reflecting a recovery from the impact of CO plant trouble and the effect of the planned shutdown in the prior fiscal year.
- Moving-average impact was negative (-7.5 billion yen) due to the acetic acid price mix impact arising from CO plant trouble and the impact of inventory carried over from the prior fiscal year.
- Expenses variance and others were negative (-7.6 billion yen) due to an increase in expenses associated with the start-up of a new Engineering Plastics plant and planned shutdown maintenance.

Analysis of EBITDA



*As the CO plant impact and Moving average impact are presented separately, they do not match the analysis values in the segment analysis on page 11.

Net Sales and Operating Income by Segment (Y on Y Analysis)

Unit : Billion Yen

	Net Sales				
	25/3 Results	26/3 Results	Y on Y		26/3 Forecasts*
			Change	%	
Medical / Healthcare	14.4	16.2	+1.8	+12.4%	16.0
Smart	37.3	37.7	+0.4	+1.2%	37.5
Safety	97.6	104.2	+6.5	+6.7%	104.0
Materials	183.4	161.3	-22.1	-12.0%	161.0
Engineering Plastics	248.0	254.7	+6.7	+2.7%	252.0
Others	5.8	5.4	-0.3	-5.5%	5.5
Total	586.5	579.6	-6.9	-1.2%	576.0

Unit : Billion Yen

	Operating Income				
	25/3 Results	26/3 Results	Y on Y		26/3 Forecasts*
			Change	%	
Medical / Healthcare	0.3	0.4	+0.2	+63.6%	0.4
Smart	-0.8	0.5	+1.3	—	0.3
Safety	3.9	6.1	+2.2	+55.0%	6.0
Materials	29.6	15.0	-14.7	-49.5%	15.0
Engineering Plastics	27.0	19.2	-7.9	-29.1%	18.5
Others	1.0	0.9	-0.1	-6.3%	0.8
Total	61.0	42.1	-18.9	-31.0%	41.0

EBITDA	
25/3 Results	26/3 Results
1.3	1.5
2.0	3.0
11.1	14.0
49.6	33.1
36.8	32.5
1.6	1.3
102.4	85.4

*These forecasts were announced on March 26, 2026.

Net Sales and Operating Income by Segment (Y on Y Analysis)

Unit : Billion Yen

	Net Sales							
	25/3 Results	26/3 Results	Change	%	Analysis			
					Quantity	Prices	Exchange Rate Impact	
Medical / Healthcare	14.4	16.2	+1.8	+12.4%	+1.8	-0.0	-0.1	
Smart	37.3	37.7	+0.4	+1.2%	+1.2	-0.8	+0.1	
Safety	97.6	104.2	+6.5	+6.7%	+7.5	-1.0	-1.0	
Materials	183.4	161.3	-22.1	-12.0%	-13.1	-9.0	-1.2	
Engineering Plastics	248.0	254.7	+6.7	+2.7%	+6.3	+0.4	-1.9	
Others	5.8	5.4	-0.3	-5.5%	-0.3	-	-	
Total	586.5	579.6	-6.9	-1.2%	+3.5	-10.4	-4.1	

Unit : Billion Yen

	Operating Income							
	25/3 Results	26/3 Results	Change	%	Analysis			
					Quantity	Prices	Others	Exchange Rate Impact
Medical / Healthcare	0.3	0.4	+0.2	+63.6%	+1.3	-0.0	-1.2	-0.0
Smart	-0.8	0.5	+1.3	-	+1.2	+0.1	+0.1	-0.1
Safety	3.9	6.1	+2.2	+55.0%	+2.8	-2.3	+1.7	-0.1
Materials	29.6	15.0	-14.7	-49.5%	-4.0	-6.7	-4.0	-0.6
Engineering Plastics	27.0	19.2	-7.9	-29.1%	+1.8	+2.5	-12.1	-0.4
Others	1.0	0.9	-0.1	-6.3%	-0.1	-	-	-
Total	61.0	42.1	-18.9	-31.0%	+3.1	-6.4	-15.6	-1.2

Segment Information – Results (Y on Y)

■ Medical / Healthcare

Unit : Billion Yen

	25/3 Result	26/3 Result	Y on Y	
			Change	%
Net Sales	14.4	16.2	+1.8	+12.4%
Operating Income	0.3	0.4	+0.2	+63.6%
Exchange Rate USD/JPY	153	151		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+1.3	Sales volume increased in both Life Sciences and Healthcare
Prices	-0.0	
Others	-1.2	Increased expenses due to increased sales volume and higher research and development cost

【YoY】 Sales & OP Up

Life Sciences Sales Up (+2.4%)

Net sales increased due to increased sales volume of chiral columns and sales of stationary phases for pharmaceutical manufacturing in Europe.

Healthcare Sales Up (+40.6%)

The cosmetics and health food markets in Japan and overseas remained strong. Sales of applications for supplements were particularly strong, with significant growth in equol, leading to increased revenue.

Segment Information – Results (Y on Y)

Smart

Unit : Billion Yen	25/3	26/3	Y on Y	
	Result	Result	Change	%
Net Sales	37.3	37.7	+0.4	+1.2%
Operating Income	-0.8	0.5	+1.3	-
Exchange Rate USD/JPY	153	151		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+1.2	Increase in sales volume of epoxy resin
Prices	+0.1	Decrease in raw material price
Others	+0.1	(+) Decrease in expenses due to a withdrawal from the organic semiconductor business in December 2024 (-) Increase in allocation of corporate-wide expenses

【YoY】 Sales & OP Up

Functional Products Sales Up (+2.9%)

Net sales of caprolactone derivatives decreased due to price competition in China and foreign exchange fluctuation. Net sales of cycloaliphatic epoxies increased due to an expansion in market share, mainly in Europe and the US, and a recovery in demand for electronic materials market particularly for electronic substrates.

Advanced Technology Sales Down (-0.8%)

Net sales of solvents for electronic materials increased due to steady semiconductor market trend. Although the polymers for photoresists business performed well due to expanded sales activities, net sales remained flat year-on-year due to inventory adjustments by customers. Net sales of high performance films decreased due to a decrease in sales volume of display film for in-vehicle application, despite a recovery trend in demand for release films for battery applications.

Segment Information – Results (Y on Y)

■ Safety

Unit : Billion Yen

	25/3 Result	26/3 Result	Y on Y	
			Change	%
Net Sales	97.6	104.2	+6.5	+6.7%
Operating Income	3.9	6.1	+2.2	+55.0%
Exchange Rate USD/JPY	153	151		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+2.8	Increase in sales volume of inflators
Prices	-2.3	Production mix impact, tariff impact and increase in raw material cost
Others	+1.7	Productivity improvement at a production site in North America and cost reduction

【YoY】 Sales & OP Up

Mobility Sales Up (+9.0%)

Although the same period of the previous fiscal year was affected by issues such as the Japanese automobile certification misconduct issue, in FY2026/3, sales of inflators increased due to factors such as the recovery of production by Chinese automotive manufacturers as a result of government stimulus measures in the Chinese market, and the expansion of sales through the addition of new production lines in India.

Regarding the impact of U.S. tariffs, price pass-through initiatives are being implemented as planned, despite some timing differences.

Industry Sales Down (-17.6%)

From the fiscal year ended March 2025, we received orders for new businesses targeting EU and China and expanded sales, but sales decreased due to a decline in sales of external sales initiators.

Segment Information – Results (Y on Y)

■ Materials

Unit : Billion Yen

	25/3 Result	26/3 Result	Y on Y	
			Change	%
Net Sales	183.4	161.3	-22.1	-12.0%
Operating Income	29.6	15.0	-14.7	-49.5%
Exchange Rate USD/JPY	153	151		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	-4.0	(+) Improvement of operating level at the carbon monoxide plant (-) Decrease in sales volume of acetate tow, and decline in operating level by production adjustment
Prices	-6.7	Decline in selling prices of acetate tow for local manufacturers, weaker market conditions of acetic acid, impact of exchange rate
Others	-4.0	Impact of moving average and increase in expenses of the full acquisition of Toyama Filter Tow, etc.

【YoY】 Sales & OP Down

Acetyl Sales Down (-15.0%)

Sales decreased due to lower sales volumes of acetate tow resulting from inventory adjustments mainly in local manufacturers, and the foreign exchange impacts, despite steady sales to major tobacco manufacturers.

Although sales volume of acetic acid increased following sales adjustments in the previous fiscal year due to CO plant trouble, the sales of acetic acid decreased demands for main derivative products such as vinyl acetate and pure terephthalic acid are continuously sluggish, thus the market condition of acetic acid decreased.

Chemical Sales Down (-3.1%)

Sales of cellulose acetate decreased due to a decline in demand for textile and plastics applications, although the sales volume for LCD applications increased due to an impact of subsidiary measures by Chinese government.

Regarding ethyl acetate, which was subject to sales adjustments in the previous fiscal year due to CO plant trouble, sales decreased due to weaker market conditions, despite an increase in sales volumes reflecting a recovery in supply.

Sales of 1,3-BG increased due to steady demand in cosmetic market, and sales expansion to China.

Segment Information – Results (Y on Y)

■ Engineering Plastics

Unit : Billion Yen	25/3 Result	26/3 Result	Y on Y	
			Change	%
Net Sales	248.0	254.7	+6.7	+2.7%
Operating Income	27.0	19.2	-7.9	-29.1%
Exchange Rate USD/JPY	153	151		

Operating Income (YoY)		
Analysis	Change	Main Factors for Operating Income Changes
Quantity	+1.8	Increase in sales volume of resins other than POM
Prices	+2.5	Differences in PPS production mix for AI servers and lower raw material and fuel prices
Others	-12.1	Increase in depreciation expenses and shut-down maintenance cost

【YoY】 Sales Up, OP Down

Polyplastics Co., Ltd. Sales Up (+4.7%)

Net sales of Polyplastics increased due to an increase in sales volume of LCP, despite a decrease in sales volume of POM and an exchange rate impact.

- Sales volume of POM decreased due to sluggish sales for various industrial sectors resulting from price competition.
- Sales volume of PBT increased due to steady demand for automotive applications.
- Sales volume of PPS increased due to strong demand for optical connector components used in AI server applications.
- Sales volume of LCP increased due to strong demand for cooling fans used in AI server applications and steady performance in sales of application for electronic devices such as smartphone and personal computers driven by China's consumer goods trade-in program. The plant in Taiwan, established to expand production capacity started operation in February 2025, reached full-scale operation in May 2025.
- Sales volume of COC remained unchanged compared to the previous fiscal year, as demand for environmentally friendly packaging eased due to the postponement of EU regulations to FY2030.

Daicel Miraizu Ltd. Sales Down (-6.3%)

Net sales of Daicel Miraizu decreased due to the transference the resin compound business to Novacel Co., Ltd. (equity-method affiliate) in July 2024.

Balance Sheet

Unit : Billion Yen		Mar. 31, 2025	Mar. 31, 2026	Change
Total Current Assets		395.6	403.2	+7.5
	Cash and Deposits	65.1	68.8	+3.7
	Notes and Accounts Receivable-trade	113.9	117.3	+3.4
	Inventories	177.9	174.5	-3.4
	Other	38.7	42.5	+3.9
Total Non-Current Assets		418.2	430.8	+12.6
	Property, Plant and Equipment	319.4	334.4	+14.9
	Intangible Fixed Assets	10.6	11.1	+0.4
	Investments and Other Assets	88.1	85.3	-2.8
Total Assets		813.8	833.9	+20.1
Liabilities		438.8	463.5	+24.8
	Interest-bearing Liabilities	286.1	312.2	+26.1
	Other	152.7	151.3	-1.4
Total Net Assets		375.0	370.4	-4.7
Total Liabilities and Net Assets		813.8	833.9	+20.1
Exchange Rate (USD/JPY)		150	160	

- Of the total asset increase, the foreign exchange impact was an increase of 55.1 billion yen.
- Inventories decreased by 3.4 billion yen compared to the end of FY2025/3, of which the foreign exchange impact was an increase of 6.2 billion yen. We adjusted production of acetate tow in this 4th quarter of FY2026/3 to reduce inventory and built up raw material inventories in response to potential impact from the situation in the Middle East.
- We will continue to reduce pulp inventories through a manufacturing process conversion in cellulose acetate production (Materials segment), optimize inventory levels across all segments through the use of AI, and monitor inventory levels for each business on a monthly basis.
- Property, plant and equipment increased due mainly to an investment for increase in production capacity of POM, LCP and COC in Polyplastics, and an investment for production process conversion of cellulose in Daicel.
- The increase in interest-bearing debt is primarily due to the rise in long-term borrowings related to Polyplastics' production expansion investments in Germany and China.

Cash Flow Statement

Unit : Billion Yen

		2025/3	2026/3
	Cash Flows from Operating Activities	93.4	67.8
	Cash Flows from Investing Activities	-47.9	-47.7
	Free Cash Flows	45.5	20.1
	Cash Flows from Financing Activities	-48.9	-22.8
	Other	-0.3	4.7
	Net Increase (Decrease) in Cash and Cash Equivalents	-3.6	2.1
	Cash and Cash Equivalents at End of Period	64.8	66.8


- Cash flows from operating activities were decreased to 67.8 billion yen, due to factors including a decrease in sales volume. Furthermore, cash flows from investing activities remained at a high level of -47.7 billion yen, primarily due to investments in Polyplastics' increased production plant.
- Cash flows from financing activities were -22.8 billion yen, mainly due to the redemption of bonds.

Revision of Business Segments from FY2027/3

FY2026/3

FY2027/3

Segment	Main Business
Medical / Healthcare	Life Sciences
	Healthcare
Smart	Functional Products
	Advanced Technology
Safety	Mobility
	Industry
Materials	Acetyl
	Chemical
Engineering Plastics	Polyplastics Co., Ltd.
	Daicel Miraizu Ltd.*3



Segment	Sub Segment	Main Products
High Performance Polymers		Polyacetal (POM), Polybutylene terephthalate (PBT), Polyphenylene sulfide (PPS), Liquid crystal polymer (LCP), Cyclic olefin copolymer (COC)
Materials	Acetyl	Acetate tow, Cellulose acetate for optical films (TAC)*1, Cellulose acetate*1, Biodegradable cellulose acetate(CAFBLO®)
	Chemical	Acetic acid*1, Acetic anhydride*1, Ethyl acetate, 1,3-Butylene glycol (1,3-BG), Polyglycerols, Spherical cellulose acetate particles (BELLOCEA®)*2, Water-soluble polymers (CMC)*3, AS resin*3
Safety		Automobile airbag inflators, Pyro-Fuse, Gas generators for seat belt pretensioners (PGG)
Smart	Functional Materials	Cycloaliphatic epoxies, Caprolactone derivatives, High-performance films*1
	Semiconductor Materials	Polymers for photoresists, Solvents for electronic materials
Life Sciences		Chromatographic columns/stationary phases (chiral columns and achiral columns), Separation services / purification services, Analytical services, Novel drug delivery devices, Functional food ingredients (Equol, Urolithin A, and Astrohop®, etc.), Separation membrane*4, Separation membrane module*4, Dialysis water treatment unit (MOLSEP®)*4

※1 : Changed subsegment category

※2 : Transferred from formerly Medical / Healthcare to Materials

※3 : Daicel Miraizu (formerly Engineering Plastics) has been transferred to Materials

※4 : Transferred from formerly Others segment to Life Sciences

The Current Situation in Light of Global Dynamics

While the deterioration of the situation in the Middle East has increased risks related to raw material procurement and logistics and driven up energy prices, we are proceeding with procurement via alternative routes, passing on price increases, and implementing internal cost-cutting measures. Although the outlook remains uncertain, including the impact on the supply chain, we are striving to minimize the impact on product supply and our financial performance.

■ Current Situation (as of April 30, 2026)

[Impact on Production]

- There is no impact on the operation of our plant.

[Impact on Raw Material Procurement]

- Although some raw materials are becoming increasingly difficult to obtain, there are no issues with the procurement of methanol and pulp, which are our primary raw materials.
- For methanol, while we have long sourced it from various regional suppliers, we are currently working closely with each supplier to secure supplies—including through procurement from other locations—in response to the deteriorating situation in the Middle East. Purchase prices have risen significantly. Our group uses approximately 500,000 tons annually, and a price increase of \$10 per ton would result in a cost increase of approximately 700 million yen (assuming an exchange rate of 150 yen to the U.S. dollar).
- Purchase prices for other raw materials have also risen significantly.

[Impact on Sales]

- Due to uncertainties regarding future raw material procurement and in order to ensure a stable supply, we have been adjusting shipments and revising prices for certain products since April 2026 in response to rising raw material costs.

[Impact on the Investment Plan]

- We are carefully reviewing the situation and revising our investment plans, including projects that have already been approved. 20

		2025/3 (Results)		2026/3 (Results)			2027/3 Forecasts
		1st Half	2nd Half	1st Half (Results)	2nd Half (Forecasts)	2nd Half (Results)	Full-year
Exchange rate (USD/JPY)		153	152	146	145	156	150
Raw Materials	Methanol Asian spot price (USD/ton)	332	334	307	330	320	330
	Crude Oil Dubai (USD/bbl.)	82	75	69	70	75	70
	Domestic Naphtha (JPY/kl)	77,950	74,000	64,750	63,000	66,130	65,000

*These data do not reflect the impact of deterioration of Middle East.

*The exchange rates of FY2026/3 2nd half forecasts were announced on March 26, 2026. Others were announced on November 6, 2025.

*These data do not reflect the impact of deterioration of Middle East.

- Revenue growth is projected due to factors such as increased sales volumes of engineering plastics and inflators for automotive airbags.
- Operating profit is projected to increase slightly, driven by factors such as lower sales prices for acetate tow due to intensifying competition in the local market and rising prices for pulp, a key raw material.
- Ordinary profit is expected to decline due to factors such as a decrease in dividend income resulting from the sale of cross-shareholdings and a decrease in equity in earnings of affiliates.
- Profit attributable to owners of the parent is expected to increase, partly because an impairment loss was recorded in the previous fiscal year.

Unit : Billion Yen


	26/3 Results	27/3 forecasts	Y on Y	
			Change	%
Net Sales	579.6	595.0	+15.3	+2.7%
Operating Income	42.1	42.5	+0.4	+1.0%
Ordinary Income	45.1	43.0	-2.1	-4.7%
Profit Attributable to Owners of Parent	10.2	32.0	+21.8	+214.3%
Exchange Rate USD/JPY	151	150		

	26/3 Results	27/3 Forecasts
EBITDA	85.4	87.0
ROE	2.8%	9.1%
ROIC	4.2%	4.3%
ROA	1.2%	3.9%
EPS(Yen)	38.75	125.30

Analysis of EBITDA

- Quantity impact will be positive (+15.3 billion yen). This was due to an increase in sales volume resulting from the start of operations at the expanded POM plant in the High-Performance Polymers business, improved operating rates following the resolution of issues at the CO plant, and the completion of customer inventory adjustments for acetate tow in the Materials business (scheduled for the second half of the current fiscal year).
- Price impact (except for exchange rate impact) will be negative (-14.3 billion yen) due to lower sales prices resulting from price competition in the local market for acetate tow within the Materials Business, as well as rising prices for pulp, a key raw material.
- Expenses variance and others will be negative (-4.3 billion yen) due to rising labor costs and increased R&D expenses.

Unit : Billion Yen



(Excluding foreign exchange and tariff impacts)

Net Sales and Operating Income by Segment (Forecasts)

Unit : Billion Yen

	Net Sales			
	26/3 Results	27/3 Forecasts	Change	%
High Performance Polymers	221.5	229.0	+7.5	+3.4%
Materials	195.9	194.0	-1.9	-1.0%
Safety	104.2	109.5	+5.3	+5.1%
Smart	37.7	39.0	+1.3	+3.3%
Life Sciences	18.4	21.5	+3.1	+17.1%
Others	2.0	2.0	-0.0	-1.0%
Total	579.6	595.0	+15.4	+2.7%

	Operating Income			
	26/3 Results	27/3 Forecasts	Change	%
High Performance Polymers	19.1	21.5	+2.4	+12.8%
Materials	14.8	10.7	-4.1	-27.6%
Safety	6.1	7.7	+1.6	+26.3%
Smart	0.5	1.0	+0.5	+86.6%
Life Sciences	0.9	1.3	+0.4	+49.9%
Others	0.7	0.3	-0.4	-59.2%
Total	42.1	42.5	+0.4	+1.0%

EBITDA	
26/3 Results	27/3 Forecasts
31.7	34.3
33.7	29.3
14.0	16.8
3.0	3.5
2.0	2.3
1.1	0.8
85.4	87.0

*FY2027/3 forecasts do not reflect the impact of deterioration of the Middle East.

In addition, FY2026/3 results have been reflected changes in business segment for year-on-year comparison.

Segment Information – Forecasts

■ High Performance Polymers

Unit : Billion Yen	26/3 Results	27/3 Forecasts	Y on Y	
			Change	%
Net Sales	221.5	229.0	+7.5	+3.4%
Operating Income	19.1	21.5	+2.4	+12.8%

【YoY】 Sales & OP Up

Market Growth Assumptions

Global automotive production volume: Largely unchanged (YoY)

POM market growth rate: Approximately 3–4% per year

Overall server market growth rate, including AI servers: Approximately 15–20% per year

Sales growth of LCP and PPS driven by AI server demand

- Sales volume of POM are expected to increase, as demand is steadily captured through flexible pricing initiatives. In addition, a second plant in China is scheduled to start operations in the second half of the fiscal year, establishing a local production and consumption system, which is expected to eliminate the impact of anti-dumping duties.

- Sales of LCP and PPS are expected to increase due to steady demand in AI server application.

- Sales of PBT are expected to decrease due to a decline in automotive production volume of Japanese manufactures.

- Sales of COC are expected to increase driven by higher sales volumes in environmentally friendly packaging and medical and self-medication applications.

- Regarding operating income, we aim to secure profits through the absence of planned shutdown maintenance at the Malaysia production site this fiscal year, improving rate of operation and price pass-through of higher raw material and fuel costs.

Segment Information – Forecasts

■ Materials

Unit : Billion Yen	26/3 Results	27/3 Forecasts	Y on Y	
			Change	%
Net Sales	195.9	194.0	-1.9	-1.0%
Operating Income	14.8	10.7	-4.1	-27.6%

【YoY】 Sales & OP Down

Acetyl : Sales Up (+3.6%)

Assumption of Market Growth Rate: tobacco market demand remains flat.

- Sales of acetate tow are expected to increase in full year, despite lower selling prices, as sales to major tobacco manufacturers are expected to remain unchanged from the previous fiscal year, and inventory adjustments at local manufacturers are expected to be completed in the second half of FY2027/3. In addition, we aim to increase sales volume by sales expansion to new local manufacturers.
- Sales of cellulose acetate for LCD application are expected to decrease due to substitution in protective film applications, despite efforts to capture replacement demand driven by subsidy programs in China and to expand sales to manufacturers in South Korea and the Taiwan region. Sales for textile application are expected to increase due to sales expansion, despite continues sluggish demand in the Chinese market.

Chemical : Sales Down (-7.3%)

- Sales of acetic acid and derivatives are expected to decrease. As prices for export products are expected to decline due to capacity expansions in China, we will focus on domestic sales with higher margin in order to strengthen profitability.
- Sales of 1,3-BG are expected to increase by sales expansion mainly to South-east Asia, U.S. and Europe.

Segment Information – Forecasts

■ Safety

Unit : Billion Yen

	26/3 Results	27/3 Forecasts	Y on Y	
			Change	%
Net Sales	104.2	109.5	+5.3	+5.1%
Operating Income	6.1	7.7	+1.6	+26.3%

【YoY】 Sales & OP Up

Assumption of Market Growth Rate: global automotive production volume remains largely flat (YoY).

- Despite potential risks of a decline in global automotive production, sales of automotive airbag inflators are expected to increase, driven by sales expansion mainly in China and India, with sales volumes expected to rise by slightly more than 10%. Also, we continue to implement productivity improvement initiatives at a U.S. production site, aiming to stably maintain more than 85% operational availability rate.
- Regarding the impact of U.S. tariffs, we have implemented price pass-through initiatives from 2Q of FY2026/3, and continue these initiatives in FY2027/3.
- Sales of Pyro-Fuse is expected to decrease due to OEMs revising their EV strategies, despite expanding new applications.

Segment Information – Forecasts

Smart

Unit : Billion Yen

	26/3 Results	27/3 Forecasts	Y on Y	
			Change	%
Net Sales	37.7	39.0	+1.3	+3.3%
Operating Income	0.5	1.0	+0.5	+86.6%

【YoY】 Sales & OP Up

Assumption of Market Growth Rate:

Semiconductor Materials (Solvents for electronic materials / photoresist polymers): +6.0%

Overall display market (functional films / cycloaliphatic epoxies): +3.9%

Functional Materials: Sales Up (+2.6%)

- Sales of cycloaliphatic epoxies are expected to increase, as we capture strong demand for display applications, expand market share in Europe and the U.S., and promote sales of high-value-added applications in China.
- Sales of functional films are expected to increase by sales expansion focusing on in-vehicle display applications and release films applications.
- Sales of caprolactone derivatives are expected to increase by expansion of market share in Europe and the U.S. and the acquisition of new projects.

Semiconductor Materials: Sales Up (+4.4%)

- As semiconductor market is growing continuously, sales of solvent for electronic materials and photoresist materials are expected to increase.
- Polymers for EUV resists are expected to start sales in 2Q of FY2027/3.

Segment Information – Forecasts

■ Life Sciences

Unit : Billion Yen

	26/3 Results	27/3 Forecasts	Y on Y	
			Change	%
Net Sales	18.4	21.5	+3.1	+17.1%
Operating Income	0.9	1.3	+0.4	+49.9%

【 YoY 】 Sales & OP Up

Assumption of Market Growth Rate: Health Food Market – Approximately 5%

- For chiral columns and related products, sales volume is planned to be expanded primarily in China and India to drive revenue growth.
- For health food ingredients, sales are expected to grow, as demand is expected to remain strong. Additionally, in preparation for the launch of sales in the United States—the world’s largest supplement market—we are proceeding with the acquisition of various certifications necessary for global expansion.
- With regard to our genetic analysis business in the United States, we are reviewing the business and pursuing strategic focus.

Shareholders Return

Regarding year-end dividend for the FY2026/3, we will maintain shareholders return in accordance with the following policies; "total return ratio of 40% or more" and "dividend on equity (DOE) ratio of 4% or more"


FY ended March 2026

- **Interim dividends : 30 yen per share**
- **Planned Year-end dividends : 30 yen per share**
(Annual dividends : 60 yen per share: the same as the previous fiscal year and unchanged from the previous forecast)
- **Purchased own stocks of 10.09 million shares for 13.7 billion yen**
(Period of purchase: from Nov. 2025 to Mar. 2026)


FY ending March 2027

- **Decided cancellation of 10.8 million shares**
- The annual dividends forecasts will be disclosed on May 22, 2026, concurrently with the new Mid-term Management Strategy. (The dividend policy remains unchanged)

Trends in Income Attributable to Owners of Parent and Dividends in Total Return (Unit: Billion Yen)





Trend in Shareholder Return Indices



Indicators of Capital Profitability and Stock Price

- Income attributable to owners of parent in the FY2026/3 decreased due to a decrease in operating income as well as recorded cost of impairment loss. The indicators are as follows; ROE 2.8% (-11.0pp), ROIC 4.2% (-1.9pp). **ROE and ROIC fell short of their respective corresponding cost of capital.**
- Regarding stock price indicators, **PER increased to 30.7 times due to a decrease in operating income. On the other hand, PBR remained 0.9 times, unchanged from the previous fiscal year.**
- ROE in the FY2027/3 is expected to be 9.1% (+6.3pp), ROIC in the FY2027/3 is expected to be 4.3% (+0.1pp)** reflecting a recovery in income attributable to owners of parent by the absence of extraordinary losses in the previous fiscal year, despite remaining at the same level of operating income.



※The metric of Cost of Equity is calculated by CAPM.


Appendix

Cross-shareholdings

We have continued to reduce cross-shareholdings, and as of the end of March 2026, **the ratio of consolidated net assets including deemed holdings was less than 20%**, and we will continue to further reduce cross-shareholdings.

	2025/3 Result	2026/3 Result	2027/3 Plan
Ratio of Consolidated Net Assets (excluding deemed holdings of shares)	12.2%	9.7%	9.5%
Ratio of Consolidated Net Assets (including deemed holdings of shares)	17.0%	14.8%	14.5%

Trend in Net Sales, Operating Income, and EPS



Quarterly Results for Sales and Operating Income

Unit : Billion Yen

	Net Sales							
	2025/3				2026/3			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Medical / Healthcare	3.5	3.7	3.7	3.6	3.8	3.8	4.4	4.2
Smart	10.3	9.3	8.9	8.8	9.5	8.7	9.3	10.3
Safety	23.3	23.8	25.7	24.8	24.5	25.3	27.3	27.1
Materials	44.5	44.0	40.7	54.2	40.3	36.9	41.2	42.9
Engineering Plastics	62.7	61.8	62.3	61.2	59.9	62.0	64.0	68.8
Others	1.3	1.6	1.6	1.4	1.3	1.2	1.5	1.5
Total	145.6	144.1	142.9	154.0	139.3	137.8	147.7	154.8

Unit : Billion Yen

	Operating Income							
	2025/3				2026/3			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Medical / Healthcare	0.1	0.1	0.2	-0.1	0.2	0.0	0.4	-0.2
Smart	0.5	-0.3	-0.8	-0.2	0.2	0.2	-0.0	0.2
Safety	-0.0	1.4	1.7	0.9	1.6	1.1	2.4	1.1
Materials	9.1	5.3	4.8	10.5	4.4	0.6	5.5	4.5
Engineering Plastics	7.7	7.5	5.4	6.4	6.5	4.9	3.8	3.8
Others	0.1	0.2	0.4	0.3	0.1	0.3	0.2	0.3
Total	17.5	14.1	11.6	17.8	13.0	7.1	12.3	9.6

Financial Forecasts (FY ending March 2027)

Unit : Billion Yen		2026/3 Results				2027/3 Forecast			
		1Q	1st Half	2nd Half	Total(A)	1Q	1st Half	2nd Half	Total(B)
	High Performance Polymers	51.8	105.5	115.9	221.5	55.0	113.5	115.5	229.0
	Materials	48.8	94.2	101.7	195.9	44.0	92.0	102.0	194.0
	Safety	24.5	49.7	54.4	104.2	25.0	52.5	57.0	109.5
	Smart	9.5	18.2	19.6	37.7	9.3	19.0	20.0	39.0
	Life Sciences	4.3	8.5	9.9	18.4	4.7	10.0	11.5	21.5
	Others	0.5	1.0	1.0	2.0	0.5	1.0	1.0	2.0
Net Sales		139.3	277.1	302.5	579.6	138.5	288.0	307.0	595.0
	High Performance Polymers	6.7	11.7	7.4	19.1	4.2	10.5	11.0	21.5
	Materials	4.2	4.6	10.2	14.8	1.8	2.6	8.1	10.7
	Safety	1.6	2.7	3.4	6.1	0.4	2.5	5.2	7.7
	Smart	0.2	0.4	0.1	0.5	0.0	0.5	0.5	1.0
	Life Sciences	0.2	0.4	0.5	0.9	0.0	0.2	1.1	1.3
	Others	0.2	0.4	0.3	0.7	0.1	0.2	0.1	0.3
Operating Income		13.0	20.1	21.9	42.1	6.5	16.5	26.0	42.5
Ordinary Income		12.3	20.4	24.8	45.1	7.0	17.0	25.6	43.0
Profit Attributable to Owners of Parent		9.6	18.8	-8.6	10.2	5.0	10.0	26.0	27.0
(ref.) Exchange Rate USD/JPY		145	146	156	151	150	150	150	150

*FY2027/3 forecasts do not reflect the impact of deterioration of the Middle East.

In addition, FY2026/3 results have been reflected changes in business segment for year-on-year comparison.

Capital Expenditures, Depreciation and Amortization and R&D




Unit : Billion Yen	Capital Expenditures		Depreciation and Amortization		R&D	
	2025/3 Results	2026/3 Results	2025/3 Results	2026/3 Results	2025/3 Results	2026/3 Results
Medical / Healthcare	0.9	1.4	1.1	1.1	2.7	3.0
Smart	2.3	2.4	2.8	2.5	5.0	4.0
Safety	11.0	9.6	7.1	7.8	7.2	7.6
Materials	11.5	22.4	19.9	18.0	3.5	3.4
Engineering Plastics	43.3	36.5	9.5	13.1	7.3	7.3
Others / Corporate	0.3	0.6	0.6	0.4	0.3	0.2
Total	69.5	72.8	41.0	42.9	25.9	25.6

Unit : Billion Yen	Capital Expenditures		Depreciation and Amortization		R&D	
	2026/3 Results	2027/3 Forecasts	2026/3 Results	2027/3 Forecasts	2026/3 Results	2027/3 Forecasts
High Performance Polymers	35.5	27.0	12.4	12.5	7.1	8.4
Materials	23.6	23.0	18.8	18.5	4.3	5.0
Safety	9.6	7.0	7.8	9.0	7.7	8.5
Smart	2.4	3.5	2.4	2.5	4.1	4.0
Life Sciences	1.4	2.5	1.1	1.0	2.2	2.5
Others / Corporate	0.4	0.5	0.4	0.5	0.2	0.1
Total	72.8	63.5	42.9	44.0	25.6	28.5

*For comparison with the previous fiscal year, the results for the fiscal year ended March 2026 reflect changes in segment classification. 37

Trend in Capital Expenditures, Depreciation and Amortization and R&D

Unit : Billion Yen



Notes Regarding Forward-Looking Statements

- **The purpose of this document is to provide information and not to persuade any individual to take any action in response to the information contained in this document. Daicel has made the greatest possible effort to prepare this document with accurate information. The information in this document, however, may include risks or inaccuracy, and we do not guarantee the accuracy or reliability of this information.**
- **The reader is advised that the use of the information in this document is at your own risk. Any investment according to the prospects, target values, etc. appearing in this document might result in a loss. Daicel accepts no responsibility for such an eventuality.**

- **All rights reserved by Daicel Corporation.**
- **This document shall not be copied or distributed to a third party without the permission of Daicel Corporation.**

This document is an English translation of a statement written originally in Japanese for reference. The Japanese original should be considered as the primary version.